|
|
|
|
|
|
|
|
"New" Treatment Agents
|
|
|
|
|
Antibodies
|
|
|
|
Anti-Inflammatory Drugs
|
Phelynbutyrate
|
|
|
Bevacizumab
|
Poly-ICLC
|
|
|
Bortezomib
(Velcade)
|
Rapamycin
(Rapamune)
|
|
|
Cabergoline
|
Retinoids
(Accutane, Fenretinide,
etc.)
|
|
|
CCI-779
|
Rituximab
|
|
|
Cetuximab
(EGFR inhibitor)
|
Riluzole
|
|
|
Cimetidine
|
R115777
(Zarnestra)
|
|
|
Clomipramine
|
Vorinostat,
Suberoylanilide Hydroxamic A. (SAHA), Zolinza
|
|
|
CpG-ODN
|
STI571
(Gleevec, Imatinib) |
|
|
Dexamethasone
|
Sagopilone (ZK-EPO)
|
|
|
Desferoxamine (DFO)
|
Surgifoam |
|
|
Etoposide
(VP-16)
|
Suramin |
|
|
Everolimus
|
Tamoxifen
(Nolvadex) |
|
|
Flavopiridol
(inhibitor of cyclin dependent kinases)
|
Thalidomide
(Thalomid) |
|
|
Fluvastatin
|
Tipifarnib |
|
|
GPI
15427 (PARP inhibitor)
|
Trastuzumab
|
|
|
Lobradimil
|
Troglitazone |
|
|
Lonafarnib
(Sarasar, SCH66336)
|
Valproic
Acid |
|
|
Nonsteroidal
Anti-Inflamm.Drugs (Celebrex,
etc.)
|
Vatalanib (VEGFR tyrosine kinase inhibitor) |
|
|
O6-Benzylguanine (O6-BG)
|
YM155 |
|
|
OSI-774
(Erlotinib, Tarceva)
|
ZD1839
(Gefitinib, Iressa) |
|
|
|
|
|
|
|
|
Noteworthy Protocols
|
|
|
|
|
C5R
Protocol
|
Individualised Therapy |
|
|
|
|
|
|
|
|
Ongoing Research
|
|
|
|
|
Alternating Electric Fields (TTFields) |
Immunotherapy
|
|
|
Anticonvulsants |
Inhibition
of Cell Signalling Channels
|
|
|
Antiangiogenesis |
Interferon
|
|
|
Antisense
Therapy |
Kinase Inhibitors
|
|
|
Anti-TNF Treatment |
Myeloablative Chemotherapy
|
|
|
Apoptosis |
Monoclonal
Antibodies
|
|
|
Bioreductive Antitumor Agents |
mRNA |
|
|
Cancer
Stem Cells |
Nanoparticles |
|
|
Cyclooxygenase |
Noscapine |
|
|
Differentiation Agents |
Photodynamic Therapy |
|
|
Drug
Delivery |
Somatostatin |
|
|
Gene
Therapy |
Stem
Cells |
|
|
Inhibition of Growth Factor Receptors Signaling |
Survivin |
|
|
Hemopexin |
Targeted Therapy |
|
|
Hyperthermia |
Toxin
Therapy |
|
|
Hypoxia
|
Tumor
Necrosis Therapy |
|
|
|
|
|
|
|
|
Treatment/Disease
Related Complications |
|
|
|
|
Anticonvulsant
Pathology |
Neoplastic
Fever |
|
|
Blood Diseases and
Disorders |
Neoplastic Meningitis |
|
|
Brain
Inflammation |
Neurologic
Complications |
|
|
Cardiological
Diseases |
Cancer
Pain |
|
|
Chemoresistance and DNA repair mechanism |
Obesity |
|
|
Collateral damage in nontargeted
tissues
|
Paraneoplastic
Neurological Disorders |
|
|
Chemotherapy-Induced Phatology
|
Plateau Waves |
|
|
Diarrhea
|
Pneumonia |
|
|
Edema
|
Pseudoprogression
|
|
|
Effects on
Liver
|
Radiation
Related
Pathology
|
|
|
Endocrine
Morbidity
|
Radionecrosis |
|
|
Fatal Outcome
|
Radioresistance
|
|
|
Fatigue
|
Malignization
and Recurrence
|
|
|
Gastric
Damage
|
Secondary
Adrenal Insufficiency
|
|
|
Hydrocephalus
|
Seizures
|
|
|
Induced Second
Neoplasm
|
Spinal Cord
Compression
|
|
|
Infections
|
Spondilodiscitis
|
|
|
Leptomeningeal
Diseases
|
Surgery
Related Pathology
|
|
|
Long
Term Complications
|
Thromboembolism |
|
|
Malnutrition
|
Transplant
|
|
|
Miscellany
(Hemorrhagic
cystitis, etc.)
|
|
|
|
Multifocal
Tumor Recurrences
|
|
|
|
|
